Longboard Pharmaceuticals, Inc. ((LBPH)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Longboard Pharmaceuticals, Inc. is conducting a Phase 3 study titled ‘A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathy.’ The study aims to evaluate the long-term safety, efficacy, and tolerability of LP352 in treating seizures in patients with developmental and epileptic encephalopathy (DEE). This research is significant as it could provide new treatment options for a challenging condition.
The intervention being tested is LP352, an experimental drug administered orally or through a G-tube/PEG tube. It is designed to manage seizures in DEE patients by titrating to the highest tolerated dose.
The study follows an interventional, single-group model without masking, focusing primarily on treatment. Participants undergo a screening, titration, maintenance, taper, and follow-up phase over approximately 14 months.
The study began on February 12, 2025, with its last update submitted on July 8, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
For investors, this study could impact Longboard Pharmaceuticals’ stock performance positively if LP352 proves effective, given the unmet needs in the DEE treatment market. The study’s progress could also influence investor sentiment and attract attention from competitors in the epilepsy treatment space.
The study is currently ongoing, with further details available on the ClinicalTrials portal.